billHR7787Event Wednesday, March 4, 2026Analyzed

To amend title VII of the Public Health Service Act to strengthen the mental health workforce, and for other purposes.

Bearish
Impact2/10

Summary

HR7787 is an early-stage bill authorizing a mental health provider loan forgiveness program. It has been referred to committee with no companion bill, zero appropriations, and minimal legislative momentum. Market impact is negligible at this stage. Real market data shows AMN Healthcare at $20.65, up 12.6% over 30 days, and Centene at $53.22, up 62.55% over 30 days, driven by other factors unrelated to this procedural bill.

See which stocks are affected

Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.

Already have an account? Log in

Key Takeaways

  • 1.HR7787 is a procedural authorization bill at the earliest committee referral stage with no funding and no Senate companion.
  • 2.Market impact is negligible; no stock movement can be attributed to this bill based on available data.
  • 3.Both AMN Healthcare and Centene have seen strong recent gains (+12.6% and +62.55% respectively over 30 days) driven by other market factors, not this legislation.

Market Implications

No near-term market implications. HR7787 is a procedural health workforce authorization bill with zero appropriations, no legislative momentum, and no identifiable path to enactment in the current session. Investors should monitor committee hearings or a companion Senate bill introduction as triggers for further analysis. Current price action in AMN Healthcare ($20.65, +12.6% monthly) and Centene ($53.22, +62.55% monthly) reflects completely unrelated market dynamics.

Full Analysis

What happened: HR7787 was introduced on March 4, 2026, by Rep. Troy Carter (D-LA) and referred to the House Committee on Energy and Commerce. It has 4 sponsors (all House members) and no companion Senate bill. The bill authorizes a loan deferment and forgiveness program for mental health providers who work for at least 5 years in designated shortage areas, with forgiveness up to $200,000 in principal and interest. The bill is at the earliest procedural stage. Money trail: This is a pure authorization bill with zero appropriated funding. Section 1 adds a new section to the Public Health Service Act authorizing the Secretary of HHS to establish the program, but no dollar amount is provided for program operations. Any actual spending would require a separate appropriations bill. Authorizations do not guarantee funding; without appropriations, the program cannot exist. Structural winners and losers: At this procedural stage, there are no structural winners or losers. If the bill eventually passed with funding, mental health staffing companies like AMN Healthcare could face reduced temporary staffing demand over the long term, while managed care organizations like Centene could see higher behavioral health utilization. However, the bill is too early-stage and unfunded to drive any near-term market action. Real market data: AMN Healthcare trades at $20.65, 7-day change +1.47%, 30-day change +12.6%. Centene trades at $53.22, 7-day change +27.26%, 30-day change +62.55%. Both stocks have moved significantly over the past month, but these moves are unrelated to HR7787. Centene's sharp 30-day gain is driven by sector-specific or company-specific factors, not this procedural mental health workforce bill. Timeline: The bill must clear the House Energy and Commerce Committee, then pass the full House, then find a Senate companion and pass the Senate, then be signed into law. No hearings, markups, or votes have been scheduled. The 119th Congress runs through 2027, but early-stage health workforce bills without appropriations or broad bipartisan sponsorship face long odds.

Intelligence Surface

Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures

Unconfirmed

No confirming evidence found yet from contracts, insider trades, or congressional activity

$$AMN▼ Bearish

What the bill does

Authorizes a voluntary loan deferment and forgiveness program for mental health professionals working full-time for 5 years in designated shortage areas; the program is unfunded in this bill and requires separate appropriations to operate.

Who must act

Secretary of Health and Human Services, contingent on future appropriations from Congress

What happens

No direct economic effect until and unless appropriations are passed; the program would increase supply of mental health providers in shortage areas, potentially reducing demand for temporary staffing solutions over a multi-year horizon.

Stock impact

AMN Healthcare provides temporary staffing of healthcare professionals including mental health providers; an increased supply of permanent providers in shortage areas could moderately reduce demand for locum tenens and temporary placements over the long term, but this bill is procedural and provides no funding.

Market Impact Score

2/10
Minimal ImpactModerateMajor Market Event

Related Presidential Actions

Executive orders & memoranda affecting the same sectors or companies

Exec OrderApr 30, 2026

Promoting Efficiency, Accountability, and Performance in Federal Contracting

This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.

Exec OrderApr 18, 2026

Accelerating Medical Treatments for Serious Mental Illness

This executive order directs the FDA to prioritize review and facilitate 'Right to Try' access for psychedelic drugs, including ibogaine compounds, that have received Breakthrough Therapy designation for serious mental illnesses. It also allocates $50 million from HHS to support state programs advancing these treatments and mandates collaboration between HHS, FDA, VA, and the private sector to increase clinical trial participation and data sharing for these drugs. The Attorney General is further directed to expedite rescheduling reviews for approved Schedule I psychedelic substances.